Advanced Proteome Therapeutics Corporation is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the. | April 13, 2021
Advanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement
Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8)
( APC or the Company ) is pleased to announce that it has increased its previously announced private placement financing (see March 1
st, 2021 news release) from up to 6,097,561 units of the Company ( units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.
Advanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement
Advanced Proteome Therapeutics Corporation (
TSXV: APC) (FSE: 0E8) ( APC or the Company ) announces that, subject to the approval of the TSX Venture Exchange (the
Exchange ), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.
Finder s fees may be payable in accordance with the policies of the Exchange. All securities issued in connection with the private placement are subject to a 4-month hold period in Canada.
Advanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO
Advanced Proteome Therapeutics Corporation
(TSXV: APC) (FSE: 0E8)
( APC or the Company ), is pleased to announce that Dr. Benjamin Krantz will be joining the Company s US subsidiary Advanced Proteome Therapeutics Inc. ( APTI ) as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1
st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.
Benjamin Krantz MD, MBA is the Chief Fellow in hematology/oncology at New York University Langone Medical Center and is currently on the Board of Directors at APTI. He completed his residency in internal medicine at New York-Presbyterian Hospital - Columbia University Medical Center during which time he analyzed investigator intellectual property disclosures as a Columbia Technology Ventures fellow. He subseque